PhRMA floating DTC guidelines draft

Share this article:

A draft of proposed voluntary guidelines for DTC advertising is circulating among Pharmaceutical Research and Manufacturers of America (PhRMA) members. A vote on the principles containted in the draft is expected sometime this summer, said PhRMA communications head Ken Johnson.
"The goal is to make DTC more educational and informational and less promotional," said Johnson.
The draft, written by PhRMA staff, is the latest effort by the group to draw up voluntary guidelines for DTC, a cause championed by former PhRMA chairman and Abbott chief Miles White. Past efforts have foundered amid member disagreement, but the initiative has taken on new urgency since the withdrawal of Vioxx, with DTC under withering scrutiny in Washington.
Current PhRMA chairman Bill Weldon, of Johnson & Johnson, vowed to press the effort in remarks at the group's annual meeting last March. "Several of the companies in this room have adopted guiding principles for direct to consumer advertising and are using them to help educate consumers," Weldon told PhRMA delegates, adding that the best approaches "underscore the right way to use medicines ... better balance information about risks and benefits ... and help consumers understand that all medicines have side effects that are best discussed with one's doctor."

Share this article:
close

Next Article in News

Email Newsletters

More in News

Doctors want to know how CMS plans to display Sunshine payment data

Doctors want to know how CMS plans to ...

Physician and industry trade groups are asking CMS to explain how context will be provided to the general public around the dollar sums drugmakers ascribe to doctors for things like ...

Pfizer Q2 sales slip, but still beat expectations

Pfizer Q2 sales slip, but still beat expectations

Patent losses and lost co-promotion agreements put a dent in sales.

Lack of marketing partner delays Afrezza launch

Lack of marketing partner delays Afrezza launch

Afrezza was heralded as one of the most innovative diabetes products of the last decade. So, why hasn't MannKind set a firm launch date for the product?